ArticlePatient safety in surgery2021
Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty.
Article in Patient safety in surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- [2024 American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guideline: Management of Osteoarthritis of the Hip (summary) interpretation].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025Guideline
- Perioperative Dexamethasone Is Associated With a Reduced Risk of Periprosthetic Joint Infection Following Aseptic Revision Total Hip and Knee Arthroplasty.Arthroplasty today · 2026Article
- The Efficacy and Safety of Tranexamic Acid in Revision Total Knee and Total Hip Arthroplasty: A Systematic Review and Meta-Analysis.Arthroplasty today · 2026Article
- Tranexamic Acid Versus no Tranexamic Acid in Spinal Tumor and Metastasis Surgery-Meta-Analysis.Global spine journal · 2026Review
- Tranexamic Acid is Safe and Effective in Reducing Blood Loss and Transfusion Rates in Nearly all Patients Undergoing Total Hip and Knee Arthroplasty.Arthroplasty today · 2026Article
- The safety and efficiency of a new strategy to remove the well-fixed cementless acetabular components in revision hip arthroplasty: a retrospective comparative study.BMC musculoskeletal disorders · 2026Article
- Impact of Anemia on Outcomes Following Total Hip Replacement Surgery and Patient Prognosis.Orthopaedic surgery · 2026Review
- Article
- The Impact of Tranexamic Acid on Blood Loss Management in Primary Total Knee Arthroplasty: A Comprehensive Review.Cureus · 2024Review
- The Use of Regional Anesthesia to Reduce Blood Loss in Isolated Limb Perfusion (ILP)-A Novel Approach.Journal of clinical medicine · 2023Article
- Does drainage affect development of heterotopic ossification after total hip arthroplasty?The Journal of international medical research · 2022Article
- Risk of Mortality among Patients with Gastrointestinal Bleeding with Early and Late Treatment with Tranexamic Acid: A Population-Based Cohort Study.Journal of clinical medicine · 2022Article
- Correction to: Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty.Patient safety in surgery · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroudIntravenous tranexamic acid (TXA) has been shown to reduce blood loss in patients undergoing total joint arthroplasty without systemic complications. There is limited evidence of its effectiveness in revision procedures. This study evaluated intravenous TXA effect on blood loss, transfusion rates, and length of hospital stay in revision joint replacement.
methodsOne-hundred revision total joint arthroplasty patients were retrospectively reviewed [44 revision total hip arthroplasty (THA) and 54 revision total knee arthroplasty (TKA)] who underwent surgery from 2013 to 2016. Fifty-four revision joint patients (23 THA and 31 TKA) received intravenous TXA intra-operatively, while 46 revision joint patients (23 THA/TKA) did not. Primary outcome measures were blood loss, transfusion rates, and length of hospital stay.
resultsThe mean blood loss difference between revision THA patients who received TXA vs. not receiving TXA was 180ml in revision THA patients (p < .005). Mean length of hospital stay was 6 days in non-TXA vs. 3 days in TXA patients (p < .001). Eighteen patients received transfusions in the non-TXA revision TKA group compared to nine patients in the TXA revision TKA group (p < .001). Average length of hospital stay was 5 days in the non-TXA revision TKA group compared to 3 days in the TXA revision TKA group (p < .003). There was no increased risk of thromboembolic complications in TXA groups for either procedure.
conclusionsIntravenous TXA reduced length of hospital stay in both revision cohorts, decreased blood loss in revision THA and decreased the rate of transfusion in revision TKA without an increase in thromboembolic complications. LEVEL OF EVIDENCE: Level III (Case-control study).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.